Formula Five for Biotech IT
Being a Biotech CIO, or How to StopWorrying and Love Rapid Change
The Changing Role of CIO in the Biopharmaceutical Industry
Advanced Therapies for Patients Suffering from PAH
How to Nurture a Biotech? Sometimes, Like a Teenager
Nicholas Ventresca, SVP & CIO, ARIAD Pharmaceuticals, Inc. [NASDAQ:ARIA]
Building a Quality-Focused IT Foundation for a Biopharmaceutical...
Andy Newsom, SVP, CIO, CSL Behring
Thank you for Subscribing to CIO Applications Weekly Brief
Clinical Trial Technology: Drive Adoption with People
By Dawn Niccum, Director, Quality Assurance, inSeptionGroup
Clinical drug development has seen similar advances and continues to accelerate. We are now talking about organizing disparate data available in real time at the click of a button. Clinical trial management has moved from the use of spreadsheets and simple listings to charts, graphs, and meaningful metrics.
The most critical piece of all these technology advances is having the right people and processes to harness their power. Advanced technology can be dwarfed by forgetting to bring the people along in the journey. People with years of experience can often be overwhelmed by new technologies. Robust change management needs to be part of the technology implementation. This includes reviewing and updating processes to leverage the technology.
In the early days of implementing Electronic Data Capture (EDC), many companies would give a brief training session and leave the sites, monitors, and data managers to determine how to use the technology.
Only when the users of the technology were brought along for the journey, the industry began to see efficiencies including faster data availability, decreased data cleaning, and shorter times to data base lock.
The next wave of technology adoption included separate systems for clinical trial management (CTM), randomization and drug distribution (Interactive Response Systems – IxRS), laboratory data, etc. Again, these technologies were developed primarily by information technology experts and senior level functional representatives. Only when the everyday user is given the opportunity to view and interact with the systems, the adoption goes from a slow to a rapid trajectory.
With the adoption of ICH E6(R2)–Integrated Addendum to ICH E6(R1): Guideline for good clinical practice, the expectation from regulators is that the use of data is optimized to demonstrate the risk and vendor management and also the overall management of the clinical trial. In the addendum section to 5.18.3, ICH states “The sponsor should develop a systematic, prioritized, risk-based approach to monitoring clinical trials.” This section goes on to describe activities that may be conducted using centralized monitoring. Both risk based monitoring technology and the accompanying complex statistical analysis are essential to conduct centralized monitoring activities.
Also, in ICH E6(R2), section 5, Quality Management, addresses using risk based approach to managing the overall quality of the clinical trial. Use of technologies and tools to help with risk identification has also seen a similar upswing as risk management is no longer just a best practice but required.
To avoid similar resistance to the implementation of these technologies as was seen with EDC, companies need to continue to change management activities. Don’t forget to bring people along for the journey.